Kymera Therapeutics, Inc. is a US-based pharmaceutical company with a Risk Rating Score of 27.5, indicating a medium risk level. Specializing in ESG-focused biotechnology, Kymera is revolutionizing disease treatment through targeted protein degradation. Their innovative Pegasus platform utilizes the body's natural protein recycling system to eliminate disease-causing proteins in previously untreatable conditions. With a focus on unexplored pathways, Kymera is at the forefront of drug discovery, offering new treatment possibilities for patients.